Welcome to the AHPBA The mission of Americas Hepato-Pancreato-biliary Association is to disseminate knowledge, foster research and innovation, advance education and training and encourage multidisciplinary collaboration.

Australia and New Zealand Hepatic, Pancreatic and biliary Association Incorporated

Victorian Hepato Pancreato biliary Surgery Group consists a group of highly trained surgeons specialized in surgery of liver, pancreas, biliary system and gallbladder.

The Habib™ EndoHPB Catheter is the first Radio Frequency (RF) ablation catheter indicated in the U.S. for malignant or benign tissue ablation in the pancreatic and biliary tract.

ELLA-CS, s.r.o. - Czech manufacturer of medical equipment for gastrointestinal tract

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the acquisition, development and commercialization of novel therapeutics for the treatment of cancer. Puma in-licenses the global development and commercialization rights to PB272 neratinib, oral , PB272 neratinib, intravenous and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX neratinib tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Union in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. Puma’s licensing partners have also received marketing authorization to commercialize NERLYNX in Canada, Israel, and several countries in Europe, Greater China, South America and Southeast Asia. NERLYNX is a registered trademark of Puma Biotechnology, Inc. Puma Biotechnology was founded by Alan Auerbach in 2010 and is headquartered in Los Angeles, California. Mr. Auerbach previously founded and served as Chief Executive Officer and President of Cougar Biotechnology, Inc., a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion. Additional information may be found at www.pumabiotechnology.com. /

?? META Description ??

The Primary Sclerosing Cholangitis (PSC) Trust is dedicated to discovering the cause and cure of PSC and related conditions.

Medlight SA is a swiss medical compagny founded in 1997 who produces a large game of catherers for an optimal endoscopic illumination. Recommended in most of the approved applications of Photodynamic Therapy (PDT) Designs new catheters for future PDT applications

Dr Michael Hatzifotis, a Laparoscopic Surgeon in Greenslopes, Brisbane, QLD specializes in Weight Loss Surgery, General Surgery and Hepato-Pancreato-biliary Surgery